GSK submits sBLA seeking expanded indication for Flulaval Quadrivalent
3 February 2016 | By Victoria White
The submission seeks an expanded indication for Flulaval Quadrivalent in the US for children six months through 35 months of age...
List view / Grid view
News
EC approves osimertinib in EGFR T790M mutation-positive NSCLC
3 February 2016 | By Victoria White
The European Commission (EC) has granted conditional marketing authorisation for AstraZeneca's Tagrisso (AZD9291, osimertinib) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Incentives and collaborations required to tackle superbugs, says GlobalData
2 February 2016 | By GlobalData
A GlobalData analyst says increased collaboration and further financial incentives are required to fight the mounting threat posed by superbugs...
Tecan simplifies large molecule bioanalysis
Tecan has launched a fully automated affinity purification solution for the extraction of large biomolecules, such as proteins, antibodies and antibody-drug conjugates. This set-up takes advantage of the new Thermo Scientific™ MSIA™ Streptavidin EVO microcolumns, which have been specifically designed for use on Tecan’s proven Freedom EVO® platform. In combination…
Easily measure cancer cell death in a co-culture with KILR™ Assays from DiscoverX
2 February 2016 | By DiscoverX
DiscoverX Corporation announced the launch of the KILR Cytotoxicity Assay, a pioneering approach to accelerate the development of cancer immunotherapy drugs...
Targovax submits study protocol for ONCOS-102 to Spanish authorities
2 February 2016 | By Victoria White
Targovax has submitted a study protocol to the regulatory authorities in Spain to assess ONCOS-102 in patients with malignant pleural mesothelioma...
Citius announces Phase 2a data for haemorrhoid treatment
2 February 2016 | By Victoria White
Citius is aiming for its combination cream to become the first FDA-approved prescription product to treat haemorrhoids in the US...
Daiichi Sankyo expands access to its clinical trial data
2 February 2016 | By Victoria White
Daiichi Sankyo has announced that it will share its clinical trial data to qualified researchers through the clinicalstudydatarequest.com system...
Abbott to acquire diagnostics company Alere
1 February 2016 | By Victoria White
Abbott has announced that it is to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership.
EMA validates Gilead’s Type II variation application for Truvada for PrEP
1 February 2016 | By Victoria White
The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP...
Sartorius grows by double digits in sales and profit in 2015 – positive outlook for 2016 – targets for 2020 updated
1 February 2016 | By Sartorius
Sartorius grew very dynamically again in 2015 according to its preliminary figures and further increased its profitability...
BMS, Pfizer and Portola team up to bring andexanet alfa to Japan
1 February 2016 | By Victoria White
Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
Do asthma and COPD exist? Experts call for a new approach to patient management
1 February 2016 | By Victoria White
Defining a patient’s symptoms using the historical diagnostic labels of asthma and COPD is an outdated approach, according to experts...
Headline results from SWITCH 2 trial of Tresiba announced
29 January 2016 | By Victoria White
SWITCH 2 is the first of two trials comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine in patients with type 2 diabetes...
CHMP adopts positive opinion of Empliciti in multiple myeloma
29 January 2016 | By Victoria White
Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein...
